Unity Total Liab from 2010 to 2025
| UBX Stock | USD 1.83 0.13 7.65% |
Total Liabilities | First Reported 2016-12-31 | Previous Quarter 33 M | Current Value 31.2 M | Quarterly Volatility 42 M |
Check Unity Biotechnology financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Unity Biotechnology's main balance sheet or income statement drivers, such as Net Interest Income of 1.8 M, Interest Income of 1.5 M or Depreciation And Amortization of 1.5 M, as well as many indicators such as Price To Sales Ratio of 104, Dividend Yield of 0.0 or PTB Ratio of 2.66. Unity financial statements analysis is a perfect complement when working with Unity Biotechnology Valuation or Volatility modules.
Unity | Total Liab |
Latest Unity Biotechnology's Total Liab Growth Pattern
Below is the plot of the Total Liab of Unity Biotechnology over the last few years. It is the total amount of all liabilities that a company has, including both short-term and long-term liabilities. Unity Biotechnology's Total Liabilities historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Unity Biotechnology's overall financial position and show how it may be relating to other accounts over time.
| Total Liab | 10 Years Trend |
|
Total Liab |
| Timeline |
Unity Total Liab Regression Statistics
| Arithmetic Mean | 83,471,979 | |
| Geometric Mean | 64,500,202 | |
| Coefficient Of Variation | 62.39 | |
| Mean Deviation | 47,873,018 | |
| Median | 73,439,000 | |
| Standard Deviation | 52,077,621 | |
| Sample Variance | 2712.1T | |
| Range | 127M | |
| R-Value | (0.78) | |
| Mean Square Error | 1121.7T | |
| R-Squared | 0.61 | |
| Significance | 0.0003 | |
| Slope | (8,571,028) | |
| Total Sum of Squares | 40681.2T |
Unity Total Liab History
About Unity Biotechnology Financial Statements
Unity Biotechnology investors use historical fundamental indicators, such as Unity Biotechnology's Total Liab, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Unity Biotechnology. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Total Liabilities | 31.2 M | 41.3 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| ZLAB | Zai Lab | |
| ASLE | AerSale Corp | |
| ATS | AT S Austria |
Additional Tools for Unity Stock Analysis
When running Unity Biotechnology's price analysis, check to measure Unity Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Unity Biotechnology is operating at the current time. Most of Unity Biotechnology's value examination focuses on studying past and present price action to predict the probability of Unity Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Unity Biotechnology's price. Additionally, you may evaluate how the addition of Unity Biotechnology to your portfolios can decrease your overall portfolio volatility.